4.1 Type 2 Diabetes: Incretins, SGLT2i & Comorbidity Alignment

4.1 Type 2 Diabetes: Incretins, SGLT2i & Comorbidity Alignment

BCACP Exam Anchor: Modern ambulatory diabetes management has shifted from a glucocentric paradigm to an organ-protective, comorbidity-driven framework. Under the current ADA Standards of Care, clinicians must select disease-modifying agents—specifically SGLT2 inhibitors and GLP-1 receptor agonists with proven cardiovascular and renal benefits—independent of baseline A1C, individualized A1C targets, or background metformin use. BCACP exam questions heavily test comorbidity matching, drug-specific renal cutoffs, adverse effect profiles, and metabolic benefits.

1. The Comorbidity-Driven Treatment Framework

When managing adult patients with type 2 diabetes mellitus (T2D), the clinical assessment begins with identifying four critical comorbid phenotypes:

1. Atherosclerotic Cardiovascular Disease (ASCVD) or High Cardiovascular Risk: (Defined as established CAD, prior MI, stroke/TIA, PAD, carotid stenosis, or age $\ge 55$ with $\ge 2$ additional risk factors [dyslipidemia, hypertension, smoking, albuminuria, obesity]).
   • First-Line / Preferred: GLP-1 Receptor Agonist with proven CV benefit (semaglutide, dulaglutide, liraglutide) OR SGLT2 Inhibitor with proven CV benefit (empagliflozin, dapagliflozin, canagliflozin).
   • Dual GIP/GLP-1 RA (Tirzepatide): Demonstrates exceptional A1C and weight reduction with emerging CV benefit data (SURPASS/SURMOUNT).
2. Heart Failure (HFrEF, HFmrEF, or HFpEF):
   • First-Line / Preferred: SGLT2 Inhibitor (empagliflozin or dapagliflozin) with proven reduction in HF hospitalizations and cardiovascular mortality across the entire ejection fraction continuum.
3. Chronic Kidney Disease (CKD with Albuminuria: eGFR 20–60 mL/min/1.73m² or UACR ≥30 mg/g, especially UACR >300 mg/g):
   • First-Line / Preferred: SGLT2 Inhibitor (canagliflozin, empagliflozin, dapagliflozin) to prevent CKD progression and CV events. If SGLT2i is not tolerated or contraindicated, prioritize a GLP-1 RA with proven renal outcomes (e.g., semaglutide from the FLOW trial).
4. Weight Management / Obesity Primary Goal:
   • Very High Efficacy: Tirzepatide (dual GIP/GLP-1 RA), Semaglutide SubQ (GLP-1 RA).
   • High Efficacy: Dulaglutide (high dose 3.0–4.5 mg), Liraglutide (up to 1.8 mg or 3.0 mg for weight management).

2. Incretin-Based Therapies: GLP-1 RAs & Dual GIP/GLP-1 RAs

Incretin hormones (Glucagon-Like Peptide-1 [GLP-1] and Glucose-Dependent Insulinotropic Polypeptide [GIP]) are gut-derived peptides secreted in response to nutrient ingestion. They stimulate glucose-dependent insulin secretion, suppress postprandial glucagon release, delay gastric emptying, and promote central satiety.

Clinical Pharmacology of GLP-1 RAs & Dual Incretins

• Semaglutide (Ozempic SubQ, Rybelsus Oral):
  • Dosing SubQ: Start 0.25 mg once weekly $\times 4$ weeks (tolerability titration; not glycemic dose), increase to 0.5 mg weekly. If additional glycemic/weight control needed, increase to 1.0 mg weekly after $\ge 4$ weeks, then max 2.0 mg weekly.
  • Oral Semaglutide (Rybelsus): Co-formulated with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) for gastric absorption. Must be taken upon waking with $\le 4$ oz plain water only, at least 30 minutes before any food, beverages, or other oral medications (Start 3 mg daily $\times 30$ days, titrate to 7 mg daily, max 14 mg daily).
• Dulaglutide (Trulicity SubQ):
  • Dosing: Start 0.75 mg once weekly. Titrate every 4 weeks to 1.5 mg, 3.0 mg, and max 4.5 mg weekly.
• Liraglutide (Victoza SubQ):
  • Dosing: Start 0.6 mg daily $\times 1$ week, increase to 1.2 mg daily, max 1.8 mg daily.
• Tirzepatide (Mounjaro SubQ):
  • Mechanism: First-in-class dual GIP and GLP-1 receptor agonist. Synergistic GIP receptor activation enhances insulin sensitivity and glucagonostatic balance while augmenting adipose lipid buffering.
  • Dosing: Start 2.5 mg once weekly $\times 4$ weeks (initiating dose), increase to 5.0 mg weekly. Titrate by 2.5 mg increments every 4 weeks as needed to 7.5 mg, 10.0 mg, 12.5 mg, and max 15.0 mg once weekly.
  • Efficacy: SURPASS clinical trial program demonstrated average A1C reductions of 2.0% to 2.6% and body weight reductions of 15% to 22%, superior to selective GLP-1 RAs and basal insulin.

Safety Warnings, Adverse Effects & Monitoring

• Boxed Warning (Thyroid C-Cell Tumors): All GLP-1 RAs and dual GIP/GLP-1 RAs carry a black box warning based on rodent thyroid C-cell adenomas. Strictly contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Gastrointestinal Tolerability: Nausea, vomiting, diarrhea, and constipation are dose-dependent. Mitigate by slow titration, reducing meal portion sizes, and avoiding high-fat/fried foods.
• Pancreatitis Risk: Discontinue promptly if persistent severe abdominal pain radiating to the back occurs. Avoid in patients with active or unexplained recurrent pancreatitis.
• Diabetic Retinopathy Complication: Rapid, abrupt reductions in plasma glucose ($\Delta \text{A1C} > 2\%$) may transiently worsen pre-existing diabetic retinopathy (observed in SUSTAIN-6). Ensure baseline dilated eye examinations.
• Gallbladder Disease: Increased incidence of cholelithiasis and cholecystitis associated with rapid weight loss.

3. SGLT2 Inhibitors: Cardiorenal Protection

Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors act in the proximal convoluted tubule of the kidney to block the reabsorption of filtered glucose and sodium, promoting glucosuria (~60–80 g/day), natriuresis, and osmotic diuresis.

Comparative SGLT2 Inhibitor Pharmacology

Critical Safety Pearls & Periprocedural Management

• Euglycemic Diabetic Ketoacidosis (euDKA): SGLT2 inhibitors lower blood glucose while stimulating glucagon release and promoting lipolysis and hepatic ketogenesis. Patients present with metabolic acidosis (anion gap $>12$, $\text{serum HCO}_3^- < 18\text{ mEq/L}$) with normal or minimally elevated blood glucose ($<250\text{ mg/dL}$). Precipitating triggers include acute surgical stress, severe dehydration, prolonged fasting, alcohol excess, or sudden insulin dose reduction.
• Periprocedural Withholding Protocol: Withhold empagliflozin, dapagliflozin, and canagliflozin for at least 3 days (and ertugliflozin for 4 days) prior to major elective surgery or procedures requiring prolonged fasting.
• Genital Mycotic Infections & Fournier Gangrene: Glucosuria promotes fungal overgrowth (Candida vulvovaginitis and balanitis). Counsel on perineal hygiene. Rare necrotizing fasciitis of the perineum (Fournier gangrene) requires immediate surgical debridement and broad-spectrum IV antibiotics.
• Renal Hemodynamics: Initiation triggers a transient 10–30% drop in eGFR within 2–4 weeks due to restored tubuloglomerular feedback and afferent arteriolar constriction (reducing toxic intraglomerular hypertension). This reversible dip does not signify acute tubular damage and is followed by long-term renal preservation.

4. Metformin, DPP-4i, Sulfonylureas & TZDs

Metformin (Biguanide)

• Mechanism: Activates hepatic AMP-activated protein kinase (AMPK), reducing hepatic gluconeogenesis and glycogenolysis while mildly improving peripheral insulin sensitivity.
• Renal Dosing Protocol:
  • $\text{eGFR} \ge 45\text{ mL/min/1.73m}^2$: Full dosing permitted (up to 2000–2550 mg/day in divided doses; or 2000 mg ER once daily with evening meal).
  • $\text{eGFR } 30\text{ to } 44\text{ mL/min/1.73m}^2$: Maximum daily dose is 1000 mg/day. Initiation in treatment-naive patients is generally not recommended; if already taking metformin, reduce dose by 50%.
  • $\text{eGFR} < 30\text{ mL/min/1.73m}^2$: Strictly Contraindicated due to risk of lactic acidosis.
• Iodinated Radiocontrast Protocol: Withhold metformin at the time of or prior to iodinated contrast procedures in patients with $\text{eGFR } 30\text{ to } 60\text{ mL/min/1.73m}^2$, history of hepatic impairment, alcoholism, or heart failure. Re-evaluate eGFR 48 hours post-procedure before resuming.
• Vitamin B12 Deficiency: Long-term metformin use impairs intestinal B12 absorption. Screen serum B12 annually, especially in patients with peripheral neuropathy symptoms or macrocytic anemia.

DPP-4 Inhibitors (Gliptins: Sitagliptin, Linagliptin, Saxagliptin, Alogliptin)

• Place in Therapy: Inhibit dipeptidyl peptidase-4 enzyme, prolonging endogenous GLP-1/GIP half-life. Intermediate glycemic efficacy (A1C reduction ~0.5–0.7%), weight neutral, low hypoglycemia risk.
• Renal Dosing: All require dose reduction in renal impairment except Linagliptin (Tradjenta 5 mg QD), which undergoes non-renal (fecal/biliary) elimination.
• Heart Failure Hospitalization Warning: Saxagliptin (SAVOR-TIMI 53) and Alogliptin (EXAMINE) are associated with increased heart failure hospitalizations; avoid in patients with heart failure or at high risk.
• Clinical Rule: Do not combine a DPP-4 inhibitor with a GLP-1 RA (redundant mechanism, no additive glycemic benefit, increased cost).

Sulfonylureas (SUs: Glipizide, Glimepiride, Glyburide)

• Mechanism: Block ATP-sensitive potassium channels on pancreatic $\beta$-cells, causing continuous, glucose-independent insulin secretagogue activity.
• Risks: High risk of hypoglycemia and weight gain (~2–4 kg). Long-term accelerated $\beta$-cell exhaustion.
• Agent Selection in Renal Impairment / Elderly:
  • Glyburide: Avoid (Beers Criteria). Generates active renal metabolites that accumulate in CKD, causing severe, prolonged, and fatal hypoglycemia.
  • Glipizide: Preferred sulfonylurea in CKD and older adults. Inactive hepatic metabolites; safer renal clearance profile.

Thiazolidinediones (TZDs: Pioglitazone)

• Mechanism: Peroxisome proliferator-activated receptor-gamma (PPAR-$\gamma$) agonist. Increases peripheral insulin sensitivity in skeletal muscle and adipose tissue.
• Cardiovascular Safety: Contraindicated in NYHA Class III or IV heart failure (causes sodium/water retention in collecting ducts leading to edema and HF exacerbation).
• Fracture & Bladder Cancer Risks: Increases distal extremity fractures in postmenopausal women; avoid in active bladder cancer.
• Unique Benefit: Proven histological resolution of MASH (Metabolic Dysfunction-Associated Steatohepatitis) and durable glycemic control.